Literature DB >> 29180467

YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.

Akira Ooki1, Maria Del Carmen Rodriguez Pena2, Luigi Marchionni3, Wikum Dinalankara3, Asma Begum4, Noah M Hahn3,4,5, Christopher J VandenBussche2, Zeshaan A Rasheed4, Shifeng Mao6, George J Netto2,3,5, David Sidransky1, Mohammad O Hoque7,3,5.   

Abstract

Overcoming acquired drug resistance remains a core challenge in the clinical management of human cancer, including in urothelial carcinoma of the bladder (UCB). Cancer stem-like cells (CSC) have been implicated in the emergence of drug resistance but mechanisms and intervention points are not completely understood. Here, we report that the proinflammatory COX2/PGE2 pathway and the YAP1 growth-regulatory pathway cooperate to recruit the stem cell factor SOX2 in expanding and sustaining the accumulation of urothelial CSCs. Mechanistically, COX2/PGE2 signaling induced promoter methylation of let-7, resulting in its downregulation and subsequent SOX2 upregulation. YAP1 induced SOX2 expression more directly by binding its enhancer region. In UCB clinical specimens, positive correlations in the expression of SOX2, COX2, and YAP1 were observed, with coexpression of COX2 and YAP1 particularly commonly observed. Additional investigations suggested that activation of the COX2/PGE2 and YAP1 pathways also promoted acquired resistance to EGFR inhibitors in basal-type UCB. In a mouse xenograft model of UCB, dual inhibition of COX2 and YAP1 elicited a long-lasting therapeutic response by limiting CSC expansion after chemotherapy and EGFR inhibition. Our findings provide a preclinical rationale to target these pathways concurrently with systemic chemotherapy as a strategy to improve the clinical management of UCB.Significance: These findings offer a preclinical rationale to target the COX2 and YAP1 pathways concurrently with systemic chemotherapy to improve the clinical management of UCB, based on evidence that these two pathways expand cancer stem-like cell populations that mediate resistance to chemotherapy. Cancer Res; 78(1); 168-81. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29180467      PMCID: PMC5754245          DOI: 10.1158/0008-5472.CAN-17-0836

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Lin28B/Let-7 Regulates Expression of Oct4 and Sox2 and Reprograms Oral Squamous Cell Carcinoma Cells to a Stem-like State.

Authors:  Chian-Shiu Chien; Mong-Lien Wang; Pen-Yuan Chu; Yuh-Lih Chang; Wei-Hsiu Liu; Cheng-Chia Yu; Yuan-Tzu Lan; Pin-I Huang; Yi-Yen Lee; Yi-Wei Chen; Wen-Liang Lo; Shih-Hwa Chiou
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

Review 2.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

3.  A gp130-Src-YAP module links inflammation to epithelial regeneration.

Authors:  Koji Taniguchi; Li-Wha Wu; Sergei I Grivennikov; Petrus R de Jong; Ian Lian; Fa-Xing Yu; Kepeng Wang; Samuel B Ho; Brigid S Boland; John T Chang; William J Sandborn; Gary Hardiman; Eyal Raz; Yoshihiko Maehara; Akihiko Yoshimura; Jessica Zucman-Rossi; Kun-Liang Guan; Michael Karin
Journal:  Nature       Date:  2015-02-25       Impact factor: 49.962

4.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

5.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.

Authors:  Antonina V Kurtova; Jing Xiao; Qianxing Mo; Senthil Pazhanisamy; Ross Krasnow; Seth P Lerner; Fengju Chen; Terrence T Roh; Erica Lay; Philip Levy Ho; Keith Syson Chan
Journal:  Nature       Date:  2014-12-03       Impact factor: 49.962

6.  Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.

Authors:  Russell D Klein; Carolyn S Van Pelt; Anita L Sabichi; Jorge Dela Cerda; Susan M Fischer; Gerhard Fürstenberger; Karin Müller-Decker
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

7.  Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1.

Authors:  Run Fan; Nam-Gyun Kim; Barry M Gumbiner
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

Review 8.  Unravelling cancer stem cell potential.

Authors:  Benjamin Beck; Cédric Blanpain
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

9.  Prostaglandin E2 promotes intestinal tumor growth via DNA methylation.

Authors:  Dianren Xia; Dingzhi Wang; Sun-Hee Kim; Hiroshi Katoh; Raymond N DuBois
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

10.  Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins.

Authors:  B V V G Reddy; Kenneth D Irvine
Journal:  Dev Cell       Date:  2013-03-11       Impact factor: 12.270

View more
  34 in total

1.  Concurrent Control of the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: a New Prospect for the Therapeutic Potential of Lipoxin A4.

Authors:  Kumari Asha; Natalie Balfe; Neelam Sharma-Walia
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

2.  Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness.

Authors:  Hirofumi Omori; Kuniaki Sato; Takafumi Nakano; Takahiro Wakasaki; Satoshi Toh; Kenichi Taguchi; Takashi Nakagawa; Muneyuki Masuda
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-04       Impact factor: 4.553

3.  Human Epididymis Protein 4 and Lewis y Enhance Chemotherapeutic Resistance in Epithelial Ovarian Cancer Through the p38 MAPK Pathway.

Authors:  Jian Gao; Liancheng Zhu; Huiyu Zhuang; Bei Lin
Journal:  Adv Ther       Date:  2021-11-05       Impact factor: 3.845

Review 4.  The Hippo pathway: an emerging role in urologic cancers.

Authors:  Bekir Cinar; Esma Alp; Marwah Al-Mathkour; Ava Boston; Abdulrahman Dwead; Kezhan Khazaw; Alexis Gregory
Journal:  Am J Clin Exp Urol       Date:  2021-08-25

5.  Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.

Authors:  Ke Zhu; Liu Xiaoqiang; Wen Deng; Gongxian Wang; Bin Fu
Journal:  Lipids Health Dis       Date:  2021-10-27       Impact factor: 3.876

Review 6.  The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.

Authors:  Akira Ooki; Kensei Yamaguchi
Journal:  Gastric Cancer       Date:  2021-08-16       Impact factor: 7.701

7.  Arsenic promotes the COX2/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells.

Authors:  Akira Ooki; Asma Begum; Luigi Marchionni; Christopher J VandenBussche; Shifeng Mao; Max Kates; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-02-14       Impact factor: 7.396

Review 8.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

9.  Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy.

Authors:  Masahiro Shibata; Akira Ooki; Yoshikuni Inokawa; Pritam Sadhukhan; M Talha Ugurlu; Evgeny Izumchenko; Enrico Munari; Giuseppe Bogina; Charles M Rudin; Edward Gabrielson; Anju Singh; Mohammad O Hoque
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

10.  Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.

Authors:  Mohamed Elbadawy; Yomogi Sato; Takashi Mori; Yuta Goto; Kimika Hayashi; Megumi Yamanaka; Daigo Azakami; Tsuyoshi Uchide; Ryuji Fukushima; Toshinori Yoshida; Makoto Shibutani; Mio Kobayashi; Yuta Shinohara; Amira Abugomaa; Masahiro Kaneda; Hideyuki Yamawaki; Tatsuya Usui; Kazuaki Sasaki
Journal:  Cancer Biol Ther       Date:  2021-05-26       Impact factor: 4.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.